Last Updated on February 23, 2024 by The Health Master

FDA Maharashtra

In a significant turn of events, the Maharashtra Food and Drug Administration (FDA Maharashtra) has taken decisive action against illicit drug sales.

A surprise inspection at Arav Eye Hospital in Bhiwandi, Thane, revealed flagrant violations, prompting swift measures from regulatory authorities.

Surprise Inspection

During the surprise inspection directed by FDA Maharashtra Commissioner Abhimanyu Kale, it came to light that Arav Eye Hospital was unlawfully selling drugs without the necessary license.

The individual at the counter claimed to be a licensed pharmacist, but subsequent investigations revealed a lack of valid credentials from the Maharashtra State Pharmacy Council (MSPC).

Disturbing Pattern

The inspection reports highlighted a disturbing pattern of illegal drug sales, raising serious concerns about the legality of the establishment’s drug dispensation practices.

Further investigations exposed similar malpractices at Sadar dispensary, owned by Dr. Ashwin Bafna.

The dispensary was found distributing allopathic medicines under the guise of doctor’s letter pads, a clear violation of the Drugs and Cosmetics (D&C) Act.

Proactive Measures Taken by FDA Maharashtra

Abhimanyu Kale informed the public that in accordance with the law, drug samples were collected for testing, and a cache of drugs worth Rs. 85,325 was seized under Section 18(a) of the D&C Act, 1940.

Sales bills and relevant documentation were confiscated for further scrutiny.

Such proactive measures serve as a stern warning to establishments engaging in unlawful drug practices, reaffirming the department’s commitment to maintaining the integrity of the pharmaceutical ecosystem.

Section 18(a) of the D&C Act, 1940

Section 18(a) of the D&C Act, 1940, empowers regulatory authorities to take stringent actions against individuals or establishments found guilty of contravening the provisions of the Act.

This section specifically pertains to offenses related to the manufacture, sale, distribution, and storage of drugs or cosmetics in violation of the law.

Consequences of Violations

Violations under this section may result in the seizure of illicit drugs, imposition of fines, cancellation of licenses, or other punitive measures deemed necessary by the authorities to uphold public health and safety standards.

Upholding Public Health and Safety Standards

The FDA Maharashtra‘s actions are crucial in upholding public health and safety standards. Enforcing regulations not only protects the public from harmful drugs but also maintains the credibility of the pharmaceutical industry.

Such proactive measures serve as a deterrent, signaling the authorities’ commitment to ensuring a safe and lawful pharmaceutical ecosystem.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

For informative videos by The Health Master, click on the below YouTube icon:

• Key Notes on Revised Schedule M: Point No. 11 – Personnel
  December 20, 2024
• USFDA issued Form 483 with two observations to Aurobindo for API plant
  December 20, 2024
• NPPA fixed retail price of 65 formulations: December 2024
  December 20, 2024
• Key Notes on Revised Schedule M: Point No. 10 – Self Inspection
  December 19, 2024
• Medical Device recall: USFDA classifies recall of these catheters as ‘most serious’
  December 19, 2024
• NPPA: New Strategy to Curb Drug Price Hikes
  December 19, 2024

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

For informative videos on consumer awareness, click on the below YouTube icon: